Second Sight Medical Products Inc (EYES) Director Gregg Williams Buys 35,235 Shares of Stock

Second Sight Medical Products Inc (NASDAQ:EYES) Director Gregg Williams bought 35,235 shares of the stock in a transaction on Thursday, June 14th. The stock was acquired at an average price of $1.83 per share, with a total value of $64,480.05. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Gregg Williams also recently made the following trade(s):

  • On Monday, June 11th, Gregg Williams acquired 26,922 shares of Second Sight Medical Products stock. The shares were purchased at an average price of $1.84 per share, with a total value of $49,536.48.
  • On Friday, June 8th, Gregg Williams acquired 16,954 shares of Second Sight Medical Products stock. The shares were purchased at an average price of $1.80 per share, with a total value of $30,517.20.
  • On Wednesday, June 6th, Gregg Williams acquired 43,843 shares of Second Sight Medical Products stock. The shares were purchased at an average price of $1.92 per share, with a total value of $84,178.56.
  • On Monday, June 4th, Gregg Williams acquired 26,485 shares of Second Sight Medical Products stock. The shares were purchased at an average price of $1.95 per share, with a total value of $51,645.75.
  • On Friday, June 1st, Gregg Williams acquired 25,355 shares of Second Sight Medical Products stock. The shares were purchased at an average price of $1.99 per share, with a total value of $50,456.45.
  • On Wednesday, May 30th, Gregg Williams acquired 12,350 shares of Second Sight Medical Products stock. The shares were purchased at an average price of $1.98 per share, with a total value of $24,453.00.
  • On Thursday, May 3rd, Gregg Williams acquired 6,756,757 shares of Second Sight Medical Products stock. The shares were purchased at an average price of $1.48 per share, with a total value of $10,000,000.36.

Shares of Second Sight Medical Products traded up $0.02, hitting $1.81, during midday trading on Friday, according to Marketbeat Ratings. 107,703 shares of the stock traded hands, compared to its average volume of 304,334. The company has a market cap of $121.94 million, a price-to-earnings ratio of -3.07 and a beta of 3.15. Second Sight Medical Products Inc has a one year low of $0.90 and a one year high of $2.58.



Second Sight Medical Products (NASDAQ:EYES) last released its quarterly earnings data on Thursday, May 10th. The medical device company reported ($0.17) EPS for the quarter. The firm had revenue of $0.98 million for the quarter. Second Sight Medical Products had a negative net margin of 387.35% and a negative return on equity of 307.76%. equities analysts expect that Second Sight Medical Products Inc will post -0.56 EPS for the current year.

Several research firms have recently commented on EYES. HC Wainwright set a $5.00 price objective on Second Sight Medical Products and gave the company a “buy” rating in a report on Tuesday, May 15th. Zacks Investment Research upgraded Second Sight Medical Products from a “hold” rating to a “buy” rating and set a $2.25 price objective for the company in a report on Thursday, May 17th. Finally, ValuEngine upgraded Second Sight Medical Products from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd.

Several large investors have recently made changes to their positions in EYES. Virtu Financial LLC purchased a new position in shares of Second Sight Medical Products during the fourth quarter valued at approximately $759,000. Sigma Planning Corp purchased a new position in shares of Second Sight Medical Products during the fourth quarter valued at approximately $144,000. Glassman Wealth Services purchased a new position in shares of Second Sight Medical Products during the first quarter valued at approximately $139,000. Finally, HBK Sorce Advisory LLC boosted its position in shares of Second Sight Medical Products by 278.5% during the fourth quarter. HBK Sorce Advisory LLC now owns 94,635 shares of the medical device company’s stock valued at $181,000 after buying an additional 69,635 shares during the last quarter. 10.69% of the stock is currently owned by institutional investors.

About Second Sight Medical Products

Second Sight Medical Products, Inc, together with its subsidiaries, develops, manufactures, and markets prosthetic devices to restore functional vision of blind individuals in the United States, Canada, Europe, the Middle East, and Asia. It offers Argus II System, which treats outer retinal degenerations, such as retinitis pigmentosa.

Insider Buying and Selling by Quarter for Second Sight Medical Products (NASDAQ:EYES)

Receive News & Ratings for Second Sight Medical Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Second Sight Medical Products and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply